CDKN2A and glioblastoma: According to The Cancer Genome Atlas (TCGA) pilot project, most of the GBM acquired mutations include homozygous deletion or mutation of CDKN2A/p16 and RB1, and amplification of CDK4, CDK6, and cyclin D, which are associated with the RB signaling pathway [60].